$ABT

Neogen (NEOG) reported Q2 revenue of $222.8M, up 6.5% YoY, beating estimates. CooperCompanies (COO) reported flat revenue, missing expectations. Abbott (ABT) reported $12.59B revenue, up 13% YoY, beating estimates. Stryker (SYK) reported $6.59B revenue, up 9.4% YoY, meeting expectations. Stocks reacted accordingly to the results.

AstraZeneca, FDC, Nutricia, and others reported strong sales growth in September 2026, per Pharmarack data. AstraZeneca saw 25.1% MAT value growth and 38.1% monthly value growth. FDC and Nutricia also posted significant gains. Sun Pharma maintained its top position with 15.1% MAT value growth. The Indian Pharmaceutical Market grew 13.5% in value and 2.9% in units monthly.

Abbott's Alere division recalled 13 million pregnancy tests globally, including in the U.S., due to false positives. The tests, distributed to hospitals, can detect low hCG levels, potentially causing false results. Abbott updated instructions but did not specify how many tests were distributed in the U.S. The recall was initiated in August and posted on the FDA's website in September.

CooperCompanies (COO) underperformed peers with weak results and guidance, stock down 14%. Baxter (BAX) beat estimates with 5.3% revenue growth, stock flat. Boston Scientific (BSX) missed guidance, stock down 6.2%. Abbott Labs (ABT) grew 13%, stock up 15.4%. Neogen (NEOG) beat estimates, stock down 2%. Market update discusses shifting investor concerns.

Abbott Laboratories (ABT) shares rose 2.23% to $101.82 on Monday, marking two days of gains. The Dow Jones Industrial Average increased 0.38% to 51,850.55, while the S&P 500 Index fell 0.06% to 7,807.24.

Abbott Laboratories (ABT) reported a 13% revenue increase in Q2 2026, with comparable sales up 4.8%. The company operates in medical devices, diagnostics, nutrition, and pharmaceuticals, and has raised dividends for 54 years. ABT's dividend yield is 2.5%, with a payout ratio of 82% based on earnings and 56% based on free cash flow. The stock trades at 33.5x trailing earnings and 17x forward earnings, with recent acquisitions impacting growth metrics.

Abbott Laboratories agreed to a $385M settlement with the DOJ for alleged false claims related to contaminated infant formula sold to government programs. The settlement resolves claims that Abbott failed to meet manufacturing standards at its Michigan and Arizona facilities. The company did not admit liability. The settlement includes $348.7M to the federal government and $36.3M to state Medicaid programs. Three whistleblowers will receive $69M for their role in exposing the allegations.

Abbott Laboratories (ABT) reported $12.59B in Q2 2026 revenue, up 13%, with medical devices contributing 46%. Its adjusted earnings grew 4% to $1.31 per share. The stock is down 22.18% YTD, lagging the S&P 500 by 42 percentage points over 52 weeks. Abbott has paid dividends for 411 consecutive quarters and has a diverse portfolio, including a new cancer diagnostics segment from its Exact Sciences acquisition.

Barclays initiated coverage on Abbott Laboratories with an Overweight rating and a $120 price target, citing valuation, earnings revisions, and visibility. The stock is currently trading at $98.16, down 1.94% over 5 days and 2.76% year-to-date. Abbott recently received FDA approval for its CardioMEMS HF System.

Analysts made several rating changes: UBS upgraded Invesco (IVZ) to Buy with a $41 target, Raymond James initiated M&T Bank (MTB) as Outperform with a $250 target, Morgan Stanley upgraded Nexa Resources (NEXA) to Overweight, and others. KeyBanc upgraded Corteva (CTVA) to Overweight with a $17 target, Jefferies upgraded Ambiq Micro (AMBQ) to Buy with a $90 target, and Citi upgraded Flutter to Buy with a $91 target.